Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H3BrO3 |
| Molecular Weight | 166.958 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C(=O)CBr
InChI
InChIKey=PRRZDZJYSJLDBS-UHFFFAOYSA-N
InChI=1S/C3H3BrO3/c4-1-2(5)3(6)7/h1H2,(H,6,7)
| Molecular Formula | C3H3BrO3 |
| Molecular Weight | 166.958 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Bromopyruvate is an halogenated analogue of pyruvic acid known as an alkylating agent reacting with thiol groups of many proteins. Bromopyruvate exerts anticancer action. It is based on the impairment of energy metabolism of tumor cells by inhibiting enzymes in the glycolysis pathway (hexokinase II, glyceraldehyde 3-phosphate dehydrogenase, phosphoglycerate kinase) and the oxidative phosphorylation (succinate dehydrogenase). Bromopyruvate induces endoplasmic reticulum stress, inhibits global protein synthesis further contributing to cancer cell death. Treatment with bromopyruvate has been administered in several cancer type models both in vitro and in vivo, either alone or in combination with other anticancer therapeutic approaches. These studies clearly demonstrate bromopyruvate broad action against multiple cancer types. This compound has also antifungal and antiparasitic activity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: 3662629.0 Gene Symbol: Tb10.6k15.3850 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8429041 |
2.67 µM [IC50] | ||
Target ID: O00187|||Q9H498 Gene ID: 10747.0 Gene Symbol: MASP2 Target Organism: Homo sapiens (Human) Sources: https://adisinsight.springer.com/drugs/800038438 |
|||
Target ID: GO:0045254 | pyruvate dehydrogenase complex Sources: https://adisinsight.springer.com/drugs/800038438 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. | 2013-01 |
|
| Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation. | 2012-05 |
|
| Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of the AMP-activated protein kinase/p38MAPK/p53 signalling axis: evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. | 2011-08-01 |
|
| Analyzing the regulation of metabolic pathways in human breast cancer. | 2010-09-10 |
|
| 3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy. | 2010-08 |
|
| Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. | 2010-07 |
|
| Interleukin-7 mediates glucose utilization in lymphocytes through transcriptional regulation of the hexokinase II gene. | 2010-06 |
|
| 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. | 2010-05-28 |
|
| Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. | 2010-04-19 |
|
| The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity. | 2010-04 |
|
| 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines. | 2010-03 |
|
| Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics. | 2010-03 |
|
| Fully automated continuous flow synthesis of highly functionalized imidazo[1,2-a] heterocycles. | 2010-02-05 |
|
| Cancer as a metabolic disease. | 2010-01-27 |
|
| Role of the mitochondrion in programmed necrosis. | 2010 |
|
| Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death. | 2009-12 |
|
| Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. | 2009-11 |
|
| Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. | 2009-10-15 |
|
| Metabolic control analysis in a cellular model of elevated MAO-B: relevance to Parkinson's disease. | 2009-10 |
|
| Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. | 2009-09-18 |
|
| A one-pot synthesis of functionalized thiazoles from acid chlorides, secondary amines, ethyl bromopyruvate, and ammonium thiocyanate. | 2009-08 |
|
| Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. | 2009-07-20 |
|
| Mitochondria and energetic depression in cell pathophysiology. | 2009-05-19 |
|
| Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. | 2009-05 |
|
| The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model. | 2009-04-04 |
|
| Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. | 2009-04 |
|
| Hexokinase inhibitor screening based on adenosine 5'-diphosphate determination by electrophoretically mediated microanalysis. | 2009-04 |
|
| Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. | 2009-04 |
|
| Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. | 2009-02-26 |
|
| Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. | 2009-02-01 |
|
| Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. | 2009-02 |
|
| Senescence induction; a possible cancer therapy. | 2009-01-08 |
|
| Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA. | 2008-12 |
|
| Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. | 2008-11 |
|
| Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. | 2008-10 |
|
| Systems biology approach to identification of biomarkers for metastatic progression in cancer. | 2008-08-12 |
|
| Hamster sperm capacitation: role of pyruvate dehydrogenase A and dihydrolipoamide dehydrogenase. | 2008-08 |
|
| A novel strategy involved in [corrected] anti-oxidative defense: the conversion of NADH into NADPH by a metabolic network. | 2008-07-16 |
|
| 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. | 2008-06 |
|
| Strategies for molecular imaging dementia and neurodegenerative diseases. | 2008-06 |
|
| Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. | 2008-03-15 |
|
| The role of glucose metabolism and glucose-associated signalling in cancer. | 2008-01-18 |
|
| Revealing targeted therapy for human cancer by gene module maps. | 2008-01-15 |
|
| Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization. | 2008 |
|
| The oncoprotein H-RasV12 increases mitochondrial metabolism. | 2007-12-01 |
|
| Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports aging-related processes. | 2007-11 |
|
| Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. | 2007-09 |
|
| FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model. | 2007-06-08 |
|
| Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen. | 2007-06 |
|
| [Expression of hexokinase-II gene in human colon cancer cells and the therapeutic significance of inhibition thereof]. | 2007-04-17 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:52:53 GMT 2025
by
admin
on
Mon Mar 31 19:52:53 GMT 2025
|
| Record UNII |
63JMV04GRK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
894722
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
390013
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
430514
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
||
|
FDA ORPHAN DRUG |
736920
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
70684
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
11731
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
Bromopyruvate
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
C017092
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
62343
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
DTXSID7040940
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
214-206-5
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
100000177177
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
1113-59-3
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY | |||
|
63JMV04GRK
Created by
admin on Mon Mar 31 19:52:53 GMT 2025 , Edited by admin on Mon Mar 31 19:52:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
Expression higher in tumor cells
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|